SEARCH

SEARCH BY CITATION

References

  • Beevers S. J., Knowles R. G. and Pogson C. I. (1983) A sensitive radiometric assay for tryptophan hydroxylase applicable to crude extracts. J. Neurochem. 40, 894897.
  • Belendiuk K., Belendiuk G. W. and Freedman D. X. (1980) Blood monoamine metabolism in Huntington's disease. Arch. General Psychiatry 37, 325332.
  • Bibb J. A., Yan Z., Svenningsson P., Snyder G. L., Pieribone V. A., Horiuchi A., Nairn A. C., Messer A. and Greengard P. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl Acad. Sci. USA 97, 68096814.
  • Blanchard-Fillion B., Souza J. M., Friel T., Jiang G. C., Vrana K., Sharov V., Barron L., Schoneich C., Quijano C., Alvarez B., Radi R., Przedborski S., Fernando G. S., Horwitz J. and Ischiropoulos H. (2001) Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J. Biol. Chem. 276, 4601746023.
  • Boularand S., Darmon M. C., Ravassard P. and Mallet J. (1995) Characterization of the human tryptophan hydroxylase gene promoter. Transcriptional regulation by cAMP requires a new motif distinct from the cAMP-responsive element. J. Biol. Chem. 270, 37573764.
  • Boutell J. M., Thomas P., Neal J. W., Weston V. J., Duce J., Harper P. S. and Jones A. L. (1999) Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Mol. Genet. 8, 16471655.
  • Carter R. J., Lione L. A., Humby T., Mangiarini L., Mahal A., Bates G. P., Dunnett S. B. and Morton A. J. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19, 32483257.
  • Cash C. D. (1998) Why tryptophan hydroxylase is difficult to purify: a reactive oxygen- derived species-mediated phenomenon that may be implicated in human pathology. General Pharmacol. 30, 569574.
  • Castro M. E., Pascual J., Romón T., Berciano J., Figols J. and Pazos A. (1998) 5-HT1B receptor binding in degenerative movement disorders. Brain Res. 790, 323328.
  • Cha J.-H. J. (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23, 387392.
  • Cha J.-H. J., Kosinski C. M., Kerner J. A., Alsdorf S. A., Mangiarini L., Davies S. W., Penney J. B., Bates G. P. and Young A. B. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl Acad. Sci. USA 95, 64806485.
  • Cha J.-H. J., Frey A. S., Alsdorf S. A., Kerner J. A., Kosinski C. M., Mangiarini L., Penney J. B. Jr, Davies S. W., Bates G. P. and Young A. B. (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 981989.
  • Cornwell-Jones C. A., Decker M. W., Chang J. W., Cole B., Goltz K. M., Tran T. and McGaugh J. L. (1989) Neonatal 6-hydroxydopa, but not DSP-4, elevates brainstem monoamines and impairs inhibitory avoidance learning in developing rats. Brain Res. 493, 258268.
  • Deckel A. W., Gordinier A., Nuttal D., Tang V., Kuwada C., Freitas R. and Gary K. A. (2001) Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: effects of L-NAME on symptom progression. Brain Res. 919, 7081.
  • Delgado P. L. and Moreno F. A. (1998) Hallucinogens, serotonin and obsessive-compulsive disorder. J. Psychoactive Drugs 30, 359366.
  • Denovan-Wright E. M. and Robertson H. A. (2000) Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98, 705713.
  • DiFiglia M. (1990) Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. 13, 286289.
  • Fleckenstein A. E., Wilkins D. G., Gibb J. W. and Hanson G. R. (1997) Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J. Pharmacol. Exp. Ther. 283, 281285.
  • Frechilla D., Cobreros A., Saldise L., Moratalla R., Insausti R., Luquin M. and Del Rio J. (2001) Serotonin 5-HT (1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39, 288296.
  • Guidetti P., Reddy P. H., Tagle D. A. and Schwarcz R. (2000) Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Neurosci. Lett. 283, 233235.
  • Harper P. S., ed. (1996) Huntington's Disease, Vol. 31. W. B. Saunders Co, Philadelphia.
  • Haycock J. W., Kumer S. C., Lewis D. A., Vrana K. E. and Stockmeier C. A. (2002) A monoclonal antibody to tryptophan hydroxylase: applications and identification of the epitope. J. Neurosci. Meth. 114, 205212.
  • Hickey M. A., Reynolds G. P. and Morton A. J. (2002) The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 81, 4659.
  • Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is unstable in Huntington's disease chromosomes. Cell 72, 971983.
  • Kandasamy S. B. and Williams B. A. (1984) Hypothermic and antipyretic effects of ACTH (1–24) and alpha- melanotropin in guinea-pigs. Neuropharmacology 23, 4953.
  • Kim S. W., Park S. Y. and Hwang O. (2002) Up-regulation of tryptophan hydroxylase expression and serotonin synthesis by sertraline. Mol. Pharmacol. 61, 778785.
  • Kish S. J., Shannak K. and Hornykiewicz O. (1987) Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum. Ann. Neurol. 22, 386389.
  • Kusakabe M., Mangiarini L., Laywell E., Bates G., Yoshiki A., Hiraiwa N., Inoue J. and Steindler D. (2001) Loss of cortical and thalamic neuronal tenascin-C expression in a transgenic mouse expressing exon 1 of the human Huntington disease gene. J. Comp. Neurol. 430, 485500.
  • Lione L. A., Carter R. J., Hunt M. J., Bates G. P., Morton A. J. and Dunnett S. B. (1999) Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J.Neurosci. 19, 1042810437.
  • Luthi-Carter R., Strand A., Peters N. L., Solano S. M., Hollingsworth Z.R., Menon A. S., Frey A. S., Spektor B. S., Penney E. B., Schilling G., Ross C. A., Borchelt D. R., Tapscott S. J., Young A. B., Cha J.-H.J. and Olson J. M. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9, 12591271.
  • Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S. W. and Bates G. P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493506.
  • McKittrick C. R., Blanchard D. C., Blanchard R. J., McEwen B. S. and Sakai R. R. (1995) Serotonin receptor binding in a colony model of chronic social stress. Biol. Psychiatry 37, 383393.
  • Mockus S. M., Kumer S. C. and Vrana K. E. (1997) A chimeric tyrosine/tryptophan hydroxylase. The tyrosine hydroxylase regulatory domain serves to stabilize enzyme activity. J. Mol. Neurosci. 9, 3548.
  • Mockus S. M. and Vrana K. E. (1998) Advances in the molecular characterization of tryptophan hydroxylase. J. Mol. Neurosci. 10, 163179.
  • Morton A. J. and Edwardson J. M. (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J. Neurochem. 76, 166172.
  • Nucifora F. C. Jr, Sasaki M., Peters M. F., Huang H., Cooper J. K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V. L., Dawson T. M. and Ross C. A. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 24232428.
  • Pearson S. J., Meldrum A. and Reynolds G. P. (1995) An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease. J. Neural Transm. Gen. Sect. 102, 6773.
  • Petersén A., Mani K. and Brundin P. (1999) Recent advances on the pathogenesis of Huntington's disease. Exp. Neurol. 157, 118.
  • Reynolds G. P. and Pearson S. J. (1987) Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. Neurosci. Lett. 78, 233238.
  • Reynolds G. P., Dalton C. F., Tillery C. L., Mangiarini L., Davies S. W. and Bates G. P. (1999) Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. J. Neurochem. 72, 17731776.
  • Ross C. A., Wood J. D., Schilling G., Peters M. F., Nucifora F. C. Jr, Cooper J. K., Sharp A. H., Margolis R. L. and Borchelt D. R. (1999) Polyglutamine pathogenesis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 10051011.
  • Schauenburg H. and Dressler D. (1992) Gilles-de–la–Tourette syndrome. Nervenarzt 63, 453461.
  • Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G. P., Davies S. W., Lehrach H. and Wanker E. E. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549558.
  • Steffan J. S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.-Z., Gohler H., Wanker E., Bates G. P., Housman D. E. and Thompson L. M. (2000) The Huntington's disease protein interacts with p53 and CBP and represses transcription. Proc. Natl Acad. Sci. USA 97, 67636768.
  • Sun Y., Savanenin A., Reddy P. H. and Liu Y. F. (2001) Polyglutamine-expanded Huntingtin promotes sensitization of N-Methyl-d-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276, 2471324718.
  • Tabaddor K., Wolfson L. I. and Sharpless N. S. (1978) Ventricular fluidhomovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders. Neurology 28, 12491253.
  • Tabrizi S. J., Workman J., Hart P. E., Mangiarini L., Mahal A., Bates G., Cooper J. M. and Schapira A. H. (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47, 8086.
  • Verge D., Daval G., Marcinkiewicz M., Patey A., El Mestikawy S., Gozlan H. and Hamon M. (1986) Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J. Neurosci. 6, 34743482.
  • Volicer L., Direnfeld L. K., Freedman M., Albert M. L., Langlias P. J. and Bird E. D. (1985a) Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type. Arch. Neurol. 42, 127129.
  • Volicer L., Langlais P. J., Matson W. R., Mark K. A. and Gamache P. H. (1985b) Serotoninergic system in dementia of the Alzheimer type. Abnormal forms of 5-hydroxytryptophan and serotonin in cerebrospinal fluid. Arch. Neurol. 42, 11581161.
  • Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D. and Richardson E. P. (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559577.
  • Vrana S. L., Dworkin S. I. and Vrana K. E. (1993) Radioenzymatic assay for tryptophan hydroxylase: [3H]H2O release assessed by charcoal adsorption. J. Neurosci. Meth. 48, 123129.
  • Vrana K. E., Rucker P. J. and Kumer S. C. (1994) Recombinant rabbit tryptophan hydroxylase is a substrate for cAMP- dependent protein kinase. Life Sci. 55, 10451052.
  • Young A. B. (1993) Role of excitotoxins in heredito-degenerative neurologic diseases. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 71, 175189.